NCT06322667 · RECRUITING
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
This is a post-marketing observational study, meaning lecanemab is already approved and in use — researchers are simply watching what happens in real clinical practice. The focus is on ARIA, a type of brain swelling or bleeding that can show up on MRI scans in patients taking lecanemab. No new drug is being given; the study tracks how often ARIA occurs and how doctors respond to it.
You may qualify if
- All participants who are treated with lecanemab in routine clinical practice
You're excluded if
- None
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-23